Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity

US12195725B2 · kind B2 · utility

Assignees

• DANA-FARBER CANCER INSTITUTE, INC. · US
• The Brigham and Women's Hospital, Inc. · US
• The Broad Institute, Inc. · US
• Massachusetts Institute of Technology · US

Inventors

• Meromit Singer · Boston, US
• Alexandra Schnell · Boston, US
• Aviv Regev · Cambridge, US
• Vijay K. Kuchroo · Newton, US

Key dates

• Filing date: Oct 5, 2020
• Grant date: Jan 14, 2025
• Expiry date: May 25, 2042

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject matter disclosed herein is generally directed to tissue specific modulation of Th17 differentiation and pathogenicity by targeting tissue specific Th17 gene programs and gene targets. The tissue specific modulation may be used therapeutically to treat a disease or condition in the tissue where it arises. The subject matter disclosed herein is also directed to detecting tissue specific Th17 cells for diagnostic and therapeutic methods.